R&D Reshoring the UK pharmaceutical supply chain for future resi... Questions of supply chain security and resiliency have been growing in recent years.
Market Access Advancing medicine requires more secure supply chains We stand at the threshold of a new era for pharmaceutical supply chains, driven by breakthroughs in personalised medicine, the rising prevalence of biologics, and the integration of digital
R&D Threats impacting the pharmaceutical industry in 2024 As we approach 2024, what will the next 12 months have in store for pharma?
News Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
